An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
NANOBIOTIX will announce its fourth-quarter and full-year 2023 operational and financial update on April 24, 2024, followed by a conference call and webcast on April 25, 2024. The Company, a late-clinical stage biotechnology firm focusing on physics-based approaches for cancer treatment, will review year-end results and business activities for 2023 during the call.
NANOBIOTIX annuncerà l'aggiornamento operativo e finanziario del quarto trimestre e dell'intero anno 2023 il 24 aprile 2024, seguito da una conferenza telefonica e un webcast il 25 aprile 2024. L'azienda, che è una società biotecnologica in fase clinica avanzata e si concentra su approcci basati sulla fisica per il trattamento del cancro, esaminerà i risultati di fine anno e le attività aziendali per il 2023 durante la chiamata.
NANOBIOTIX anunciará su actualización operativa y financiera del cuarto trimestre y del año completo 2023 el 24 de abril de 2024, seguido por una llamada de conferencia y un webcast el 25 de abril de 2024. La compañía, una firma biotecnológica en etapa clínica avanzada que se enfoca en enfoques basados en la física para el tratamiento del cáncer, revisará los resultados de fin de año y las actividades empresariales de 2023 durante la llamada.
NANOBIOTIX는 2024년 4월 24일에 2023년도 4분기 및 연간 운영 및 재무 업데이트를 발표할 예정이며, 이어서 2024년 4월 25일에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 물리학 기반의 암 치료 접근법에 중점을 둔 후기 임상 단계의 생명공학 회사인 이 회사는 통화 중 2023년도의 연말 결과 및 사업 활동을 검토할 것입니다.
NANOBIOTIX annoncera sa mise à jour opérationnelle et financière pour le quatrième trimestre et l'année complète 2023 le 24 avril 2024, suivie d'une conférence téléphonique et d'un webcast le 25 avril 2024. L'entreprise, une firme biotechnologique en phase clinique avancée qui se concentre sur des approches basées sur la physique pour le traitement du cancer, passera en revue les résultats de fin d'année et les activités commerciales pour 2023 lors de l'appel.
NANOBIOTIX wird sein operatives und finanzielles Update für das vierte Quartal und das gesamte Jahr 2023 am 24. April 2024 bekannt geben, gefolgt von einer Telefonkonferenz und einem Webcast am 25. April 2024. Das Unternehmen, ein biotechnologisches Unternehmen in der späten klinischen Phase, das sich auf physikbasierte Ansätze zur Krebsbehandlung konzentriert, wird die Jahresend-Ergebnisse und Geschäftsaktivitäten für 2023 während des Anrufs überprüfen.
Positive
None.
Negative
None.
Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST
PARIS and CAMBRIDGE, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the fourth quarter and full year ended December 31, 2023, on Wednesday, April 24, 2024, after the close of the US market.
This release will be followed by a conference call and webcast on Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm CEST before the US market open. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company’s year-end results and provide an update on business activities for the fourth quarter and full year of 2023 before taking questions from participants.
Details for the call are as follows:
Live (US): 1-888-886-7786 Live France: 0 800 916 834 Live (international): 1-416-764-8658 Call me™: Click here
Participants can use guest dial-in numbers above and be answered by an operator or they can click the Call me™ link for instant telephone access to the event (dial-out). The Call me™ link will be made active 15 minutes prior to scheduled start time. A live webcast of the call may be accessed by visiting the investors section of the Company’s website at www.nanobiotix.com. It is recommended to join 10 minutes prior the event start. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in, among other, Cambridge, Massachusetts (United States).
Nanobiotix is the owner of more than 20 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
When will NANOBIOTIX announce its fourth-quarter and full-year 2023 operational and financial update?
NANOBIOTIX will announce its fourth-quarter and full-year 2023 operational and financial update on April 24, 2024.
When is the conference call and webcast scheduled for NANOBIOTIX?
The conference call and webcast for NANOBIOTIX are scheduled for April 25, 2024, at 8:00 am EDT / 2:00 pm CEST.
Who will review the year-end results and business activities for NANOBIOTIX during the conference call?
Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will review the year-end results and business activities for NANOBIOTIX during the conference call.
How can participants access the live webcast of the conference call?
Participants can access the live webcast of the conference call by visiting the investors section of NANOBIOTIX's website at www.nanobiotix.com.
Where can participants find a replay of the webcast after the conclusion of the call?
Participants can find a replay of the webcast shortly after the conclusion of the call on NANOBIOTIX's website.
nanobiotix (euronext: nano / isin: fr0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. the company’s first-in-class, proprietary technology, nanoxray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients. nanoxray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration. nbtxr3 is being evaluated in: soft tissue sarcoma (sts), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). additionally, head and neck cancer and rectal cancer trials led by nanobiotix’s taiwanese partner, pharmaengine, are underway in the asia pacific region. the company started a new preclinical research program in immuno-oncology with its lea
